Call for Abstract
Scientific Program
2nd International Conference on Bio-Pharmaceuticals, will be organized around the theme “Designing the future of Biopharma”
Asia Bio 2020 is comprised of 19 tracks and 111 sessions designed to offer comprehensive sessions that address current issues in Asia Bio 2020.
Submit your abstract to any of the mentioned tracks. All related abstracts are accepted.
Register now for the conference by choosing an appropriate package suitable to you.
- Track 1-1Pharmaceutical Nanotechnology based Systems
- Track 1-2Applications of Pharmaceutical Nanotools
- Track 1-3Challenges to Pharmaceutical Nanotechnology
- Track 1-4Advances in self-emulsifying drug delivery systems (SEDDS)
- Track 1-5Engineering of Pharmaceutical Nano systems
- Track 1-6Future Prospects of Pharmaceutical Nanotechnology
- Track 2-1Drug Repositioning
- Track 2-2Stages Involved in Drug Development
- Track 2-3Drug Targeting Systems
- Track 2-4Clinical Phases
- Track 2-5Evaluation Techniques
- Track 3-1Recent toxicological studies and its issues
- Track 3-2Pharmacoepidemiology and drug safety
- Track 3-3Current advances in the pharmacology and physiology of trp channels
- Track 3-4Clinical Pharmacology
- Track 3-5Pharmacogenetics and pharmacogenomics
- Track 4-1New drug applications and fundamental drug development
- Track 4-2Scope of contemporary pharmacy practice
- Track 4-3Ethics in pharmacy and its policies
- Track 4-4New dimensions of pharmacy practice
- Track 4-5Clinical laboratory practice
- Track 4-6Global standards in pharmacy practice
- Track 5-1Radiopharmaceutical Usage
- Track 5-2Engineering models in biomedicine
- Track 5-3Clinical laboratory sciences
- Track 5-4Biomedical data engineering
- Track 6-1Safety monitoring of medicinal products
- Track 6-2Drug safety methods
- Track 6-3Detection of ADR’s and other drug related problems
- Track 6-4Pharmacoepidemology and drug safety
- Track 6-5Set up & implementation of cosmetovigilance system
- Track 6-6Systematic monitoring the safety of cosmetics
- Track 7-1Packaging for Patient Compliance
- Track 7-2Packing technology for Drug Delivery Systems
- Track 7-3Serialization implementation challenges for Pharma Companies
- Track 7-4Regulatory Considerations-China, US, EU, Pharmacopoeia
- Track 7-5Serialization implementation challenges for Pharma Companies
- Track 8-1Major challenges in drug delivery systems
- Track 8-2Preformulation studies and accelerated stability studies
- Track 8-3Nanotechnology in drug delivery system
- Track 8-4Lipid drug delivery system
- Track 8-5Recent advances in targeted drug delivery systems
- Track 9-1Toxicology studies of plant products
- Track 9-2Industrial pharmacognosy
- Track 9-3Drugs from natural sources and its availabity
- Track 9-4Drug discovery research in pharmacognosy
- Track 9-5Phytochemistry and phytoconstituents
- Track 9-6Herbal drugs and its documentation procedures
- Track 10-1Diagnostic and bioinorganic medicinal chemistry
- Track 10-2Plant and microbial derived drugs in Drug discovery
- Track 10-3Recent advances in fluorinated pharmaceuticals based on natural products
- Track 10-4Green techniques for organic synthesis and medicinal chemistry
- Track 10-5Current developments in medicinal chemistry
- Track 10-6Advances in Drug discovery
- Track 11-1Drug discovery and design
- Track 11-2Fundamental drug development
- Track 11-3Innovations in clinical development
- Track 11-4Bio pharmaceutics and drug disposition
- Track 11-5Pharmaceutical technology
- Track 11-6Radiopharmaceuticals
- Track 11-7Pharmaceutics and drug delivery
- Track 11-8Recent advances in neuro and psycho pharmacology
- Track 12-1Industrial pharmaceutics
- Track 12-2Dosage form design, development and manufacturing
- Track 12-3Post- marketing surveillance
- Track 12-4Drug discovery and development
- Track 12-5Clinical studies
- Track 12-6Marketing
- Track 13-1Drug Discovery
- Track 13-2Pharmaceutical Packaging
- Track 13-3Quality Assurance and Quality Control
- Track 13-4Quality by Design and Quality Risk Assessment
- Track 13-5GMP & cGMP
- Track 14-1Pharma waste and its disposal
- Track 14-2Dispensing pharmacy and research chemists
- Track 14-3Clinical pharmacy & its key role in treatment
- Track 14-4Pharmacotherapy
- Track 14-5Environmental health hazards
- Track 14-6High performance genetic analysis, fluid dispensing modelling
- Track 14-7Clinical drug development and therapeutics
- Track 14-8Environmental health hazards
- Track 15-1Intellectual property law for generics and innovator rights
- Track 15-2FDA regulations and compliance strategies
- Track 15-3Novel strategies for growth in regulatory affairs
- Track 15-4Regulatory requirements for pharmaceuticals and health care products
- Track 15-5Intellectual property rights
- Track 15-6Regulatory issues, quality control and business development
- Track 15-7Novel strategies for growth in regulatory affairs
- Track 16-1Good clinical practices & good laboratory practices according to ICH
- Track 16-2Current good manufacturing practices guidelines
- Track 16-3Management of product storage, transportation and distribution
- Track 16-4Current regulations and quality standards
- Track 16-5Quality assurance, quality control and SOP
- Track 17-1Analytical IQ, OQ and PQ
- Track 17-2Modern pharmaceutical analytical techniques
- Track 17-3Analytical method development and validation
- Track 17-4Electroanalytical methods
- Track 17-5Current trends in gravimetric analysis
- Track 17-6Qualitative & quantitative elemental analysis
- Track 17-7Qualitative & quantitative elemental analysis
- Track 17-8Surface characterization techniques for chemical & physical analysis
- Track 18-1Preformulation in Drug Development
- Track 18-2Physiological Drug Environment
- Track 18-3Drug Formulation Considerations
- Track 18-4Hot Melt Extrusion
- Track 19-1Biomarker research, development and technology
- Track 19-2Disease related and drug related biomarkers
- Track 19-3Challenges and regulatory approach for biosimilars
- Track 19-4Clinical studies and clinicians prospects for biosimilars
- Track 19-5Measurable parameters for customized therapies
- Track 19-6Future of next generation biosimilars